| Identification | Back Directory | [Name]
Declaben | [CAS]
111149-90-7 | [Synonyms]
Declaben SC-39026 Lodelaben Lodelabenum Lodelabenum [inn-latin] Benzoic acid, 2-chloro-4-(1-hydroxyoctadecyl)- | [Molecular Formula]
C25H41ClO3 | [MDL Number]
MFCD00864771 | [MOL File]
111149-90-7.mol | [Molecular Weight]
425.04 |
| Chemical Properties | Back Directory | [Boiling point ]
539.8±40.0 °C(Predicted) | [density ]
1.038±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
3.09±0.25(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Anti arthritic; emphysema therapy adjunct. | [in vivo]
The mean pulmonary artery pressures of the saline/vehicle and saline/Lodelaben groups are similar, 16.4±1.1 and 17.4±0.9 mm Hg, respectively. Although, mean pulmonary artery pressure in the monocrotaline/vehicle group is 27.5±0.8 mm Hg, treatment of monocrotaline rats with Lodelaben results in significantly lower values (21.00±1.6 mm Hg, p<0.05). Saline/vehicle and saline/Lodelaben rats have only a small percentage of arteries muscularized at the alveolar wall level (1.9±1.4 and 0.4±0.4%, respectively). Treatment of monocrotaline-injected rats with Lodelaben results in a decreased percentage of alveolar wall arteries muscularized (10.0±3.6%)[2]. |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|